Chemoimmunotherapy in Older Adults With Non–Small Cell Lung Cancer
Authors:
- 1 December 2024
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 10 (12) , 1732
Abstract
To the Editor The study by Tsukita et al presents valuable insights. However, there were several critical limitations that warrant discussion, along withKeywords
This publication has 6 references indexed in Scilit:
- Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2024
- Medical management of older patients with lung cancerJapanese Journal of Clinical Oncology, 2022
- Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expressionCancer Science, 2022
- Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practicesScientific Reports, 2021
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung CancerClinical Cancer Research, 2008